Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 149-155

  Giannitsas, Konstantinos ^a   Konstantinopoulos, Angelis ^a   Patsialas, Christos ^a   Perimenis, Petros ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Adherence; PDE 5 inhibitors; Preference; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

EID: 70449352181     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Brock G., Chan J, Carrier S, et al. 2007. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. BJU Int, 99:376-82.
2. Carson C. C, Lue TF. 2005. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int, 96:257-80.
3. Dean J., Hackett GI, Gentile V, et al. 2006. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med, 3:650-61.
4. Doggrell S. 2007. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res, 19:281-95.
5. Eardley I., Mirone V, Montorsi F, et al. 2005. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int, 96:1323-32.
6. Eardley I., Montorsi F, Jackson G, et al. 2007. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int, 100:122-9.
7. Feldman H. A, Goldstein I, Hatzichristou DG, et al. 1994. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol, 151:54-61.
8. Govier F., Potempa AJ, Kaufman J, et al. 2003. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther, 25:2709-23.
9. Hanash K.A. 1997. Comparative results of goal oriented therapy for erectile dysfunction. J Urol, 157:2135-8.
10. Hatzichristou D., Vardi Y, Papp G, et al. 2005. Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials. J Urol, 174:1356-9.
11. Hatzichristou D., Haro JM, Martin-Morales A, et al. 2007. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract, 61:1850-62.
12. Hatzimouratidis K., Hatzichristou DG. 2005. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs, 65:1621-50.
13. Jiann B. P, Yu CC, Tsai JY, et al. 2003. What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res, 15:412-17.
14. Jiann B. P, Yu CC, Su CC, et al. 2006. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res, 18:146-9.
15. Kell P. D, Hvidsten K, Morant SV, et al. 2007. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int, 99:860-3.
16. Klotz T., Mathers M, Klotz R, et al. 2005. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res, 17:2-4.
17. Lee J., Pommerville P, Brock G, et al. 2006. Physician-rated patient preference and patient-and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. BJU Int, 98:623-9.
18. McCullough AR, Carson CC, Hatzichristou D. 2006. A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. Urology, 68(Suppl 3):38-46.
19. Mulhall J.P. 2004. Understanding erectile dysfunction medication preference studies. Curr Opin Urol, 14:367-73.
20. Mulhall J. P, McLaughlin TP, Harnett JP, et al. 2005. Medication utilization behaviour in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med, 2:848-55.
21. Mulhall J. P, Montorsi F. 2006. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol, 49:30-7.
22. Padma-Nathan H, Eardley I, Kloner RA, et al. 2002. 4-year update on the safety of sildenafil citrate (Viagra). Urology, 60(Suppl 2):67-90.
23. Pangkahila W.I. 2000. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians. Asian J Androl, 2:233-6.
24. Rubio-Aurioles E, Porst H, Eardley I, et al. 2006. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med, 3:1037-49.
25. Sato Y., Tanda H, Kato S, et al. 2007. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int J Urol, 14:339-42.
26. Son H., Park K, Kim SW, et al. 2004. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl, 6:117-20.
27. Souverein P. C, Egberts AC, Meuleman EJ, et al. 2002. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res, 14:259-65.
28. Steidle C. P, McCullough AR, Kaminetsky JC, et al. 2007. Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. Int J Impot Res, 19:154-60.
29. Ströberg P., Murphy A, Costigan T. 2003. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther, 25:2724-37.
30. Ströberg P., Hedelin H, Ljunggren C. 2006. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction-a realistic and feasible option in everyday clinical practice-outcomes of a simple treatment regime. Eur Urol, 49:900-7.
31. Tolrà J. R, Campana JM, Ciutat LF, et al. 2006. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med, 3:901-9.
32. von Keitz A, Rajfer J, Segal S, et al. 2004. A multicenter, randomized, double-blind, two-period crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol, 45:499-507.